Healthcare ❯ Pharmaceuticals ❯ Clinical Trials ❯ Myotonic Dystrophy
The result could change investor views on the value of Novartis' $12 billion Avidity acquisition by reducing confidence in its late‑stage neuromuscular bets and prompting a formal data review with regulators.
